Summary for Tradename: RISPERDAL

Patents:	18
Applicants:	1
NDAs:	4
2008 Sales:	$1,221,505,000
Therapeutic Class:	Antipsychotics Bipolar Agents

Latest news for RISPERDAL

Alkermes Retains Neutral Rec (Zacks.com via Yahoo! Finance)

8 February 2010, 3:07 pm

Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders (Medical News Today)

7 February 2010, 6:22 am

Lower Q3 Loss for Alkermes (Zacks.com via Yahoo! Finance)

5 February 2010, 10:14 am

Ahead of the Bell: Alkermes upgraded on 3Q results (INO News)

5 February 2010, 9:25 am

Ahead of the Bell: Alkermes upgraded on 3Q results (AP via Yahoo! Finance)

5 February 2010, 9:12 am

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics (News-Medical-Net)

4 February 2010, 11:32 pm

Alkermes reports 3Q loss, smaller than expected (AP via Yahoo! Finance)

4 February 2010, 6:21 pm

Alkermes Inc. Reports Operating Results (10-Q) (Guru Focus)

4 February 2010, 5:36 pm

Alkermes Reports Third Quarter Fiscal 2010 Financial Results (Business Wire via Yahoo! Finance)

4 February 2010, 4:00 pm

Courtesy of Yahoo News

Glossary

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Exclusivity Expiration
Ortho Mcneil Janssen	RISPERDAL	risperidone	020272	Dec 29, 1993	DISCN	No	Aug 22, 2010
Ortho Mcneil Janssen	RISPERDAL	risperidone	020272	Dec 29, 1993	DISCN	No	Feb 22, 2011
Ortho Mcneil Janssen	RISPERDAL	risperidone	020272	Dec 29, 1993	RX	No	Apr 6, 2010

Export available with Ultimate Plan subscription:

This preview shows a limited data set. Complete access is available with a Subscription Plan

Paragraph IV activity for: RISPERDAL

Drugname	Dosage	Strength	RLD	Submissiondate
risperidone	Orally Disintegrating Tablets	0.25 mg	Risperdal	4/11/2005
risperidone	Orally Disintegrating Tablets	3 mg and 4 mg	Risperdal	3/23/2005

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Ultimate Plan compare plans

$475 / One Month	$1,895 / One Year

Need an invoice? Group rate? Contact admin@DrugPatentWatch.com

Your Source for Pharmaceutical Industry Intelligence

Ultimate Plan

Search for Tradename: RISPERDAL